Activation of the P53 Pathway by the MDM2 Inhibitor Nutlin-3a Overcomes BCL2 Overexpression in a Preclinical Model of Diffuse Large B-Cell Lymphoma Associated With T(14;18)(q32;q21)

Leukemia - United Kingdom
doi 10.1038/leu.2011.28
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MDM2 Inhibitor, Nutlin 3a, Induces P53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

PLoS ONE
Multidisciplinary
2015English

Cellular Quiescence Caused by the Mdm2 Inhibitor Nutlin-3a

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

Translocations T(8;14) and T(14;18) in a Case Presenting Diffuse Large B-Cell Lymphoma.

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2001English

A Novel T(2;6)(p12;q23) Appearing During Transformation of Follicular Lymphoma With T(18;22)(q21;q11) to Diffuse Large Cell Lymphoma

Cancer Genetics and Cytogenetics
2003English

Presence of Simian Virus 40 in Diffuse Large B-Cell Lymphomas in Tunisia Correlates With Germinal Center B-Cell Immunophenotype, T(14;18) Translocation, and P53 Accumulation

Modern Pathology
Forensic MedicinePathology
2007English

Clinical Significance of T-Cell Exhaustion in Patients With Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Overexpression of FoxM1 Offers a Promising Therapeutic Target in Diffuse Large B-Cell Lymphoma

Haematologica
Hematology
2012English

Diffuse Large B-Cell Lymphoma

2020English

Direct Costs Associated With Relapsed Diffuse Large B‐Cell Lymphoma Therapies

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy